Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
GRPH Stock Summary
Top 10 Correlated ETFs
GRPH
In the News
What Makes Graphite Bio, Inc. (GRPH) a New Buy Stock
Graphite Bio, Inc. (GRPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Hundreds more tech, biotech layoffs hit Bay Area, Google real estate ally cuts jobs
About 600 more tech and biotech layoffs rocked the Bay Area job market in a fresh round of cutbacks that suggest the staffing reductions in the region have yet to run their course, new state government filings show.
Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround
Graphite Bio, Inc. (GRPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Graphite Bio: Underfollowed Gene Editing Play At An Attractive Valuation
Graphite Bio has lost roughly 60% of its value over the past twelve months and is trading with a negative enterprise value despite its prospects in gene therapy. I discuss why I believe GRPH is a prime candidate for the Compounding Healthcare “Bio Boom” Portfolio.
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
BMO Capital Sees Over 400% Upside For This Small Gene-Editing Stock
BMO Capital Markets initiated coverage on Graphite Bio Inc (NASDAQ: GRPH), with a price target of $12 and an Outperform rating. The analyst notes that Graphite's gene editing approach involves a DNA repair mechanism that is known to be less vulnerable to errors.
Best Penny Stocks to Buy Today? 3 to Watch on May 3rd
What to know about buying penny stocks on May 3rd The post Best Penny Stocks to Buy Today? 3 to Watch on May 3rd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
SomaLogic, Graphite Bio Make List of Most Promising Life Sciences Companies
Two public companies made the BioSpace list of the 30 most promising North American life sciences startups. SomaLogic Inc. ( SLGC , Financial) and Graphite Bio Inc. ( GRPH , Financial) are included in the NextGen Bio “Class of 2022.
Graphite Bio: An Important Stock To Track In The Gene Editing Space
Graphite Bio: An Important Stock To Track In The Gene Editing Space
GRPH Financial details
GRPH Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.01 | -0.4 | -2.06 | -1.76 | -2.19 | |
Operating cash flow per share | 0 | -0.26 | -1.83 | -1.6 | -1.58 | |
Free cash flow per share | 0 | -0.3 | -2.03 | -1.72 | -1.77 | |
Cash per share | 0 | 0.58 | 13.04 | 4.89 | 3.26 | |
Book value per share | -0.15 | -1.91 | 13.28 | 5.4 | 3.22 | |
Tangible book value per share | -0.15 | -1.91 | 13.28 | 5.4 | 3.22 | |
Share holders equity per share | -0.15 | -1.91 | 13.28 | 5.4 | 3.22 | |
Interest debt per share | 0.16 | 0 | 0.39 | 0.19 | 0.01 | |
Market cap | 270.61M | 632.46M | 359.47M | 182.18M | 149.38M | |
Enterprise value | 272.81M | 612.67M | -6.23M | 140.24M | -36.12M | |
P/E ratio | -1.43K | -46.57 | -6.02 | -1.89 | -1.2 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -14.24K | -72.52 | -6.8 | -2.07 | -1.66 | |
PFCF ratio | -14.24K | -61.61 | -6.14 | -1.93 | -1.48 | |
P/B Ratio | -122.01 | -9.67 | 0.94 | 0.61 | 0.81 | |
PTB ratio | -122.01 | -9.67 | 0.94 | 0.61 | 0.81 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -9.41K | -8.98 | 0.09 | -1.33 | 0.51 | |
EV to operating cash flow | -14.36K | -70.25 | 0.12 | -1.59 | 0.4 | |
EV to free cash flow | -14.36K | -59.68 | 0.11 | -1.48 | 0.36 | |
Earnings yield | 0 | -0.02 | -0.17 | -0.53 | -0.83 | |
Free cash flow yield | 0 | -0.02 | -0.16 | -0.52 | -0.68 | |
Debt to equity | -0.99 | 0 | 0.03 | 0.02 | 0 | |
Debt to assets | 367.5 | 0 | 0.03 | 0.02 | 0 | |
Net debt to EBITDA | -75.83 | 0.29 | 5.17 | 0.4 | 2.62 | |
Current ratio | 0 | 0.66 | 31.44 | 21.11 | 39.2 | |
Interest coverage | -0.36 | -337.5 | 0 | -23.03 | 0 | |
Income quality | 0.17 | 0.13 | 0.75 | 0.87 | 0.72 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0.18 | 0.11 | 0.07 | 0.12 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -12.77 | -7.82 | -2.8 | -4.51 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.21 | 4.14 | 24.84 | 14.61 | 12.59 | |
ROIC | 3.87 | 0.04 | -0.13 | -0.33 | -0.4 | |
Return on tangible assets | -31.5 | -0.6 | -0.15 | -0.3 | -0.66 | |
Graham Net | -0.15 | -1.99 | 12.42 | 4.42 | 3.17 | |
Working capital | -2.22M | -10.95M | 369.59M | 262.32M | 183.22M | |
Tangible asset value | -2.22M | -65.41M | 384.05M | 296.29M | 183.58M | |
Net current asset value | -2.22M | -66.87M | 363.8M | 249.75M | 183.15M | |
Invested capital | -0.99 | 0 | 0.03 | 0.02 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 315K | 1.54M | 2.53M | 1.43M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 1.9K | 1.22K | 114.06 | 37.91 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0.19 | 0.3 | 3.2 | 9.63 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.09 | 0.21 | -0.16 | -0.33 | -0.68 | |
Capex per share | 0 | -0.05 | -0.2 | -0.12 | -0.19 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0.18 | |
Net income per share | -0.4 | -0.38 | -0.97 | -0.39 | -0.4 | |
Operating cash flow per share | -0.4 | -0.38 | -0.24 | -0.16 | -0.79 | |
Free cash flow per share | -0.42 | -0.38 | -0.34 | -0.25 | -0.79 | |
Cash per share | 4.81 | 4.73 | 4.35 | 4.09 | 3.2 | |
Book value per share | 5.32 | 4.94 | 3.95 | 3.56 | 3.16 | |
Tangible book value per share | 5.32 | 4.94 | 3.95 | 3.56 | 3.16 | |
Share holders equity per share | 5.32 | 4.94 | 3.95 | 3.56 | 3.16 | |
Interest debt per share | 0.14 | 0.18 | 0.94 | 0.93 | -0.08 | |
Market cap | 1.29B | 958.08M | 1.03B | 993.99M | 1.06B | |
Enterprise value | 1.25B | 892.81M | 957.8M | 864.11M | 878.37M | |
P/E ratio | -14.42 | -11.18 | -4.67 | -11.05 | -11.61 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 103.93 | |
POCF ratio | -57.74 | -45.46 | -75.63 | -105.73 | -23.19 | |
PFCF ratio | -55.22 | -44.65 | -53.61 | -69.93 | -23.16 | |
P/B Ratio | 4.37 | 3.47 | 4.61 | 4.87 | 5.8 | |
PTB ratio | 4.37 | 3.47 | 4.61 | 4.87 | 5.8 | |
EV to sales | 0 | 0 | 0 | 0 | 85.81 | |
Enterprise value over EBITDA | -46.84 | -43.43 | 56.07 | -34.53 | -60.75 | |
EV to operating cash flow | -55.87 | -42.37 | -70.14 | -91.92 | -19.15 | |
EV to free cash flow | -53.43 | -41.61 | -49.72 | -60.79 | -19.13 | |
Earnings yield | -0.02 | -0.02 | -0.05 | -0.02 | -0.02 | |
Free cash flow yield | -0.02 | -0.02 | -0.02 | -0.01 | -0.04 | |
Debt to equity | 0.02 | 0.02 | 0.24 | 0.26 | 0 | |
Debt to assets | 0.02 | 0.01 | 0.19 | 0.2 | 0 | |
Net debt to EBITDA | 1.57 | 3.17 | -4.39 | 5.19 | 12.83 | |
Current ratio | 21.11 | 18.85 | 20.47 | 19.05 | 39.2 | |
Interest coverage | -12.43 | -5.05 | 0 | 0 | 2.79 | |
Income quality | 0.91 | 0.88 | 0.25 | 0.42 | 2 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 1.43 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.05 | 0.02 | 0.41 | 0.51 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -1.5 | -0.59 | -6.61 | -6.32 | -0.35 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.23 | |
Graham number | 6.94 | 6.53 | 9.31 | 5.61 | 5.3 | |
ROIC | -0.08 | -0.08 | -0.28 | -0.08 | 0.03 | |
Return on tangible assets | -0.07 | -0.07 | -0.19 | -0.08 | -0.12 | |
Graham Net | 4.35 | 4.12 | 3.24 | 3 | 3.12 | |
Working capital | 262.32M | 255.97M | 238.9M | 226.25M | 183.22M | |
Tangible asset value | 296.29M | 276.22M | 224.15M | 204.02M | 183.58M | |
Net current asset value | 249.75M | 236.54M | 188.27M | 176.57M | 183.15M | |
Invested capital | 0.02 | 0.02 | 0.24 | 0.26 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 3.29M | 2.3M | 2.36M | 3.24M | 2M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 105.63 | 80.76 | 116.68 | 422.21 | 158.45 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0.85 | 1.11 | 0.77 | 0.21 | 0.57 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.08 | -0.08 | -0.25 | -0.11 | -0.12 | |
Capex per share | -0.02 | -0.01 | -0.1 | -0.08 | 0 |
GRPH Frequently Asked Questions
What is Graphite Bio, Inc. stock symbol ?
Graphite Bio, Inc. is a US stock , located in South san francisco of Ca and trading under the symbol GRPH
Is Graphite Bio, Inc. buy or a sell ?
5 stock analysts have 5 predictions with a medium analyst target price of $4.4. The lowest prediction is $2 and the highest is $7
What is GRPH stock prediction ?
What is Graphite Bio, Inc. stock quote today ?
Graphite Bio, Inc. stock price is $3.18 today.
Is Graphite Bio, Inc. stock public?
Yes, Graphite Bio, Inc. is a publicly traded company.